Abstract: The present invention provides a novel anhydrous composition of small-molecule polysaccharides, consisting of at least a small-molecule polysaccharide and an anhydrous base. The formulation of the anhydrous composition of small-molecule polysaccharides allows the small-molecule polysaccharide to maintain a molecular size of 12-22 nm and the direct penetration of the small-molecule polysaccharide across the horny layer of skin. The present invention also provides a method of effectively maintaining skin hydration level in a subject in need thereof, comprising topically administering to the subject an anhydrous composition of small-molecule polysaccharides.

Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.

Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.

Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.

Abstract: This invention relates to a topical spray preparation for burn treatment and microbial infections on human being or animals. This non-aerosol preparation contains an antimicrobial drug, i.e., silver sulfadiazine, as is dispersed or solubilized in a cream or lotion base matrix which can be sprayed directly from a common trigger spray device. The key component of the matrix can be characterized by it having a suitable molecular weight polymer of cross-linked acrylic acid, such as Carbomers or non-ionic surfactants such as polyoxyethylene alkyl ethers, or any combination of the above materials.

Abstract: Direct compressible ibuprofen particles are formed by treating commercially available, dry ibuprofen with a hydrophilic solvent in one embodiment, a mixture of a hydrophilic solvent and one or more hydrophobic organic solvents in a second embodiment and one or more hydrophobic organic solvents in a third embodiment, to change at least the external crystalline shape of the ibuprofen from a flow-retarding shape to a free-flowing, easily compressible configuration. A typical hydrophilic solvent is water and among the hydrophobic solvents which may be used are acetone, methyl alcohol, ethyl alcohol, isopropyl and N-propyl alcohol. Direct compressible ibuprofen particles having superior flow characteristics may also be prepared by mixing commercially available, dry ibuprofen with micron size, amorphous silica gel in various formulations.